With reference to tumor specific antibody-cytokine fusion proteins, L19 antibody (targeting fibronectin)-mIL12 construct was found to induce a strong antitumor effect against fibrosarcoma tumors only after combination with PD-1 inhibition. Here, PDCD1 is linked to neoplasm.